Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsIndependent Health step‑therapy prior‑fill Coverag…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentIndependent HealthPolicy N/A

    Step therapy criteria and pharmacy prior-authorization gating based on member prescription history

    Customize your policy alerts

    Sign up for all Independent Health policy alerts

    Know when Independent Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medications subject to step therapy and the pharmacy prior authorization requirements based on members' prescription history for Independent Health formularies; applies to providers and pharmacies filling prescriptions for affected members.

    Policy Summary
    PayerIndependent Health
    PolicyStep therapy criteria and pharmacy prior-authorization gating based on member prescription history
    Policy CodePolicy N/A
    Change TypeAdministrative — no material change
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionDocument required prior fills or concurrent therapy in the member's Independent Health prescription history to allow online processing; otherwise obtain prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+listed products or product groups in this excerpt
    90 dayscommon lookback period for prior-fill checks
    120 dayslookback period for high-potency narcotics
    multipleformulary lists covered

    Coverage / Step Therapy Criteria

    Initial step therapy conditions by product

    Coverage for the listed products is approved when ALL of the following member-specific prior therapy conditions are met for each product as specified:

    Aczone (dapsone 7.5% gel): Member's Independent Health prescription history documents that generic dapsone 5% was filled within the previous 90 days.prior fill within 90 days
    ALOCRIL / bepotastine ophthalmic: Member's Independent Health prescription history documents that Zaditor or Alaway OTC was filled within the previous 90 days.prior fill within 90 days
    GLP-1 antidiabetic agents (e.g., Mounjaro, Ozempic, Rybelsus, Trulicity): Member has type 2 diabetes OR has tried any oral antidiabetic drug excluding metformin within the past 130 days.
    Policy Summary
    PayerIndependent Health
    PolicyStep therapy criteria and pharmacy prior-authorization gating based on member prescription history
    Policy CodePolicy N/A
    Change TypeAdministrative — no material change
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionDocument required prior fills or concurrent therapy in the member's Independent Health prescription history to allow online processing; otherwise obtain prior authorization.
    SourceLink
    On This Page
    Coverage / Step Therapy CriteriaAffected Products and Lookback WindowsPrior Authorization Triggers and Pharmacy DocumentationPolicy BackgroundKey DefinitionsInitial Therapy RulesStep Therapy Lookup Table
    diagnosis of type 2 diabetes OR prior oral antidiabetic fill (excluding metformin) within 130 days
    Aprepitant / certain antiemetics: Member's Independent Health prescription history documents a generic ondansetron fill within the previous 180 days.prior fill within 180 days
    Belsomra (suvorexant): Member's Independent Health prescription history documents a generic zolpidem fill within the previous 365 days.prior fill within 365 days
    Binosto (alendronate effervescent): Member's Independent Health prescription history documents alendronate filled within the previous 90 days.prior fill within 90 days
    Bromfenac ophthalmic: Member's Independent Health prescription history documents generic bromfenac ophthalmic solution 0.09% once daily filled within the previous 90 days.prior fill within 90 days
    Entacapone / Ongentys: Member's Independent Health prescription history documents concurrent use of a levodopa/carbidopa product (entacapone/Ongentys requires levodopa-carbidopa use).concurrent levodopa/carbidopa use
    Diclofenac potassium (migraine): Member's Independent Health prescription history documents a generic NSAID fill.prior NSAID fill
    Eucrisa (crisaborole) ointment: Member's Independent Health prescription history documents tacrolimus, pimecrolimus, or a topical corticosteroid fill within the previous 365 days.prior topical calcineurin inhibitor or corticosteroid fill within 365 days

    EUCRISA prior-fill criterion

    Covered without prior authorization when the following is met

    EUCRISA prior-fill: Patient has Independent Health pharmacy fill of tacrolimus, pimecrolimus, or a topical corticosteroid within the prior 365 days.365 days

    If not met, prior authorization required

    90-day prior-fill criteria

    Covered without prior authorization when ANY of the following drug-specific prior fills are present in the member's pharmacy history within 90 days

    Fetzima: Patient has venlafaxine extended-release capsule fill within the prior 90 days.90 days

    If not met, prior authorization required

    Glycopyrrolate: Patient has generic glycopyrrolate tablet fill within the prior 90 days.90 days

    If not met, prior authorization required

    Gabapentin / Horizant: Patient has gabapentin (including once-daily or HORIZANT ER) fill within the prior 90 days.90 days

    If not met, prior authorization required

    Doxercalciferol / Rayaldee: Patient has calcitriol fill within the prior 90 days.90 days

    If not met, prior authorization required

    Hydrocortisone valerate: Patient has triamcinolone fill within the prior 90 days.90 days

    If not met, prior authorization required

    Amphetamine-dextroamphetamine ER: Patient has amphetamine-dextroamphetamine extended-release capsule fill within the prior 90 days.90 days

    If not met, prior authorization required

    Namzaric: Patient has donepezil or memantine fill within the prior 90 days.90 days

    If not met, prior authorization required

    High-potency narcotics prior-fill criterion

    Covered without prior authorization when the following is met

    High-potency opioid prior-fill: Patient's Independent Health prescription history documents narcotic medication fills within the previous 120 days.120 days

    If not met, prior authorization required because these medications pose serious risks if started in a narcotic-naïve patient

    Online processing / Prior Authorization gating criteria

    Covered when the pharmacy profile documents the specific prior fill or concurrent therapy within the time window listed for the product; otherwise prior authorization is required.

    Product-specific pharmacy-history criteria: For each listed product, the pharmacy prescription history must show the specified prior fill or concurrent therapy within the stated lookback period (examples include: narcotic fill within 120 days for listed high-potency opioids; oxcarbazepine fill within 90 days for oxcarbazepine ER; concurrent entacapone or levodopa-carbidopa-entacapone within 180 days for Ongentys; immediate-release tramadol within 90 days for tramadol ER; ondansetron within 180 days for Sancuso; tretinoin or adapalene within 90 days for tazarotene topical).see product-specific nodes

    If criterion not met prior authorization is required

    Step therapy / prior therapy requirements

    Covered with criteria when the specified prior therapy is documented in Independent Health prescription history within the stated look-back period; otherwise prior authorization required.

    Tramadol ER: Online processing allowed if Independent Health prescription history documents immediate-release tramadol filled within previous 90 days; otherwise prior authorization is required.90 days
    Trintellix: Online processing allowed if Independent Health prescription history documents a generic SSRI fill (e.g., sertraline, fluoxetine, escitalopram) within the previous 90 days; otherwise prior authorization is required.90 days
    Febuxostat (Uloric): Online processing allowed if Independent Health prescription history documents allopurinol filled within the previous 90 days; otherwise prior authorization is required.90 days
    Xphozah (tenapanor): Online processing allowed if prescription history documents concurrent use of a phosphate binder within previous 120 days; otherwise prescriber must request authorization via standard process.120 days
    Sublingual zolpidem: Online processing allowed if Independent Health prescription history documents generic zolpidem filled within previous 90 days; otherwise prior authorization is required.90 days

    There are no explicit clinical exclusions stated in this portion of the policy excerpt. The coverage criteria instead implement pharmacy-history–based step therapy rules and prior-authorization gating (lookback windows and required comparator fills) rather than listing conditions or diagnoses that would categorically exclude a member from coverage.

    The policy explicitly treats the listed high-potency opioid ER and fentanyl transdermal products differently: starting these agents in a narcotic‑naïve patient is discouraged. To avoid prior authorization, the member's Independent Health prescription history must document narcotic medication fills within the prior 120 days; absent that documentation, prior authorization is required.

    Within the excerpt provided there are no statements that label any therapy or product as ‘not medically necessary’. Coverage decisions here are framed as conditional — based on documented prior fills or diagnoses in the pharmacy profile — and noncompliance with those conditions routes the claim to standard prior‑authorization review rather than an explicit non‑medical‑necessity determination.

    Affected Products and Lookback Windows

    Products AffectedNDC|plain
    EUCRISA OINTMENT 2 % EXTERNALProduct affected
    Products AffectedNDC|plain
    FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORALProduct affected
    FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORALProduct affected
    FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORALProduct affected
    FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORALProduct affected
    Products AffectedNDC|plain
    glycopyrrolate solution 1 mg/Sml oralProduct affected
    Products AffectedNDC|plain
    gabapentin (once-daily) tablet 300 mg oralProduct affected
    gabapentin (once-daily) tablet 600 mg oralProduct affected
    HORIZANT TABLET EXTENDED RELEASE 300 MG ORALProduct affected
    HORIZANT TABLET EXTENDED RELEASE 600 MG ORALProduct affected
    Products AffectedNDC|plain
    doxercalciferol capsule 0.5 mcg oralProduct affected
    doxercalciferol capsule 1 mcg oralProduct affected
    doxercalciferol capsule 2.5 mcg oralProduct affected
    RAYALDEE CAPSULE EXTENDED RELEASE 30 MCG ORALProduct affected
    Products AffectedNDC|plain
    hydrocortisone valerate ointment 0.2 % externalProduct affected
    Products AffectedNDC|plain
    amphet-dextroamphet 3-bead er capsule extended release 24 hour 12.5 mg oralProduct affected
    amphet-dextroamphet 3-bead er capsule extended release 24 hour 25 mg oralProduct affected
    amphet-dextroamphet 3-bead er capsule extended release 24 hour 37.5 mg oralProduct affected
    amphet-dextroamphet 3-bead er capsule extended release 24 hour 50 mg oralProduct affected
    Products AffectedNDC|plain
    memantine hcl-donepezil hcl capsule extended release 24 hour 14-10 mg oralProduct affected
    memantine hcl-donepezil hcl capsule extended release 24 hour 21-10 mg oralProduct affected
    memantine hcl-donepezil hcl capsule extended release 24 hour 28-10 mg oralProduct affected
    NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 7-10 MG ORALProduct affected
    Products Affected - High-potency narcoticsNDC|plain
    fentanyl patch 72 hour 100 mcg/hr transdermalProduct affected
    fentanyl patch 72 hour 25 mcg/hr transdermalProduct affected
    fentanyl patch 72 hour 12 mcg/hr transdermalProduct affected
    fentanyl patch 72 hour 50 mcg/hr transdermalProduct affected
    fentanyl patch 72 hour 75 mcg/hr transdermalProduct affected
    hydrocodone bitartrate er tablet er 24 hour abusedeterrent 100 mg oralProduct affected
    hydrocodone bitartrate er tablet er 24 hour abusedeterrent 120 mg oralProduct affected
    hydrocodone bitartrate er tablet er 24 hour abusedeterrent 80 mg oralProduct affected
    hydrocodone bitartrate er tablet er 24 hour abusedeterrent 60 mg oralProduct affected
    hydrocodone bitartrate er tablet er 24 hour abusedeterrent 40 mg oralProduct affected
    1–10 of 35
    1/4
    inv-19: Lookback fill windows — multiple windows referenced (90, 130, 180, 365 days)
    Lookback windows referenced90 days; 130 days; 180 days; 365 days
    Most common window90 days
    Longest topical/window365 days (topical therapies like EUCRISA)
    Intermediate window180 days (e.g., ondansetron, Sancuso, Ongentys concurrent therapy)
    Special GLP-1 window130 days (prior oral antidiabetic trial excluding metformin)
    inv-20: Topical prior fill lookback — 365 days
    Topical prior-fill lookback365 days (tacrolimus, pimecrolimus, or topical corticosteroid for EUCRISA)
    Action when not metPrior authorization required if no qualifying topical fill within 365 days
    Applies toEUCRISA (crisaborole) ointment
    inv-21: Standard prior fill lookback — 90 days
    Standard prior-fill lookback90 days (venlafaxine XR, glycopyrrolate, gabapentin/Horizant, calcitriol for doxercalciferol/Rayaldee, amphetamine-dextroamphetamine ER, donepezil or memantine for Namzaric)
    Action when not metPrior authorization required if no qualifying fill within 90 days
    Common product examplesFetzima, glycopyrrolate, gabapentin/Horizant, Rayaldee, amphetamine-dextroamphetamine ER, Namzaric
    inv-22: High-potency opioid prior fill lookback — 120 days
    High-potency opioid prior-fill lookback120 days (narcotic medication fills documented in Independent Health prescription history)
    RationaleThese high-potency narcotics pose serious risks if started in a narcotic‑naïve patient
    Action when not metPrior authorization required and prescription may be denied if no narcotic fill within 120 days
    inv-23: Common look-back — 90 days (additional references)
    Common look-back period90 days (used across many products such as tramadol ER, Trintellix, febuxostat, sublingual zolpidem)
    ExamplesImmediate‑release tramadol for tramadol ER; generic SSRI for Trintellix; allopurinol for febuxostat; generic zolpidem for sublingual zolpidem
    Processing implicationIf no documented fill within 90 days, prior authorization is required
    inv-24: Xphozah concurrent therapy look-back — 120 days
    Xphozah concurrent therapy look-back120 days (concurrent phosphate binder use must be documented within previous 120 days)
    Action when not metPrescriber may request authorization if pharmacy history does not document concurrent phosphate binder use
    Applies toXphozah (tenapanor) 20 mg and 30 mg

    Prior Authorization Triggers and Pharmacy Documentation

    Prior Authorization

    Obtain prior authorization when step criteria aren't met

    If the pharmacy profile does not document the required prior-fill or diagnosis within the specified lookback window for a product, the claim will be routed to prior authorization; submit a PA to avoid denial.

    • Step-therapy exceptions require PA when prior-fill criteria are not met.
    • Lookback windows vary by product (see individual entries).
    Prior Authorization

    EUCRISA: PA if no tacrolimus/pimecrolimus/topical corticosteroid in prior 365 days

    For EUCRISA ointment, prior authorization is required if the member's Independent Health pharmacy history does not show a tacrolimus, pimecrolimus, or topical corticosteroid fill within the previous 365 days.

    Prior Authorization

    Fetzima: PA if no venlafaxine ER fill in prior 90 days

    For Fetzima, prior authorization is required if the pharmacy profile does not document a venlafaxine extended‑release capsule filled within the previous 90 days.

    Prior Authorization

    Glycopyrrolate: PA if no generic glycopyrrolate tablet fill in prior 90 days

    For glycopyrrolate products, prior authorization is required when the pharmacy profile does not document a generic glycopyrrolate tablet fill within the previous 90 days.

    Prior Authorization

    Gabapentin / Amphetamine‑dextroamphetamine: PA if no specified comparator fill in prior 90 days

    For the listed gabapentin and amphetamine‑dextroamphetamine ER products, prior authorization is required if the pharmacy profile does not document the specified comparator (gabapentin or amphetamine‑dextroamphetamine ER) fill within the previous 90 days.

    Prior Authorization

    Doxercalciferol / Rayaldee: PA if no calcitriol fill in prior 90 days

    For doxercalciferol and Rayaldee products, prior authorization is required if the pharmacy profile does not document a calcitriol fill within the previous 90 days.

    Prior Authorization

    Hydrocortisone valerate: PA if no triamcinolone fill in prior 90 days

    For hydrocortisone valerate ointment, prior authorization is required if the pharmacy profile does not document a triamcinolone fill within the previous 90 days.

    Prior Authorization

    Namzaric: PA if no donepezil or memantine fill in prior 90 days

    For Namzaric (memantine–donepezil ER), prior authorization is required if the pharmacy profile does not document a donepezil or memantine fill within the previous 90 days.

    Prior Authorization

    High‑potency opioids: PA if no narcotic fills in prior 120 days

    For listed high‑potency opioid ER and patch products, prior authorization is required if the pharmacy profile does not document narcotic medication fills within the previous 120 days.

    • Applies to multiple fentanyl patches and ER opioid formulations listed in the policy.
    • These agents require documented prior narcotic use because of initiation risk in narcotic‑naïve patients.
    Denial Risk

    High‑potency opioids: PA required when 120‑day narcotic history absent

    If the pharmacy profile does not show a narcotic fill in the prior 120 days for the listed high‑potency opioids, prior authorization is required and the prescription may be denied without it.

    Prior Authorization

    Ongentys: PA if no entacapone or levodopa‑carbidopa‑entacapone use in prior 180 days

    For Ongentys, prior authorization is required if the pharmacy profile does not document concurrent entacapone or levodopa‑carbidopa‑entacapone use within the past 180 days.

    Prior Authorization

    Oxcarbazepine ER: PA if no oxcarbazepine fill in prior 90 days

    Oxcarbazepine ER requires prior authorization when the pharmacy profile does not document an oxcarbazepine fill within the previous 90 days.

    Prior Authorization

    Qelbree: PA if no prior atomoxetine fill documented

    For Qelbree, prior authorization is required if the pharmacy profile does not document a prior atomoxetine fill within the timeframe indicated in the policy.

    Prior Authorization

    Methylphenidate ER: PA if no generic methylphenidate SR/ER fill in prior 90 days

    Quillichew/Quillivant XR (methylphenidate ER) requires prior authorization if the pharmacy profile does not document a generic methylphenidate SR/ER fill within the previous 90 days.

    Prior Authorization

    Aliskiren: PA if no prior ACE and ARB fills within 180 days

    For aliskiren, prior authorization is required if the pharmacy profile does not document prior ACE inhibitor and ARB fills within the previous 180 days.

    Prior Authorization

    Sancuso: PA if no ondansetron fill in prior 180 days

    Sancuso patch requires prior authorization when the pharmacy profile does not document an ondansetron fill within the previous 180 days.

    Prior Authorization

    Serevent Diskus: PA if no concurrent inhaled corticosteroid or Spiriva use documented

    Serevent Diskus requires prior authorization if the pharmacy profile does not document concurrent inhaled corticosteroid or Spiriva use as specified in the policy.

    Prior Authorization

    Tazarotene: PA if no tretinoin or adapalene fill in prior 90 days

    Tazarotene topical products require prior authorization when the pharmacy profile does not document a tretinoin or adapalene fill within the previous 90 days.

    Prior Authorization

    Tramadol ER: PA if no immediate‑release tramadol fill in prior 90 days

    Tramadol ER products require prior authorization if the pharmacy profile does not document an immediate‑release tramadol fill within the previous 90 days.

    Denial Risk

    Tramadol ER: PA required when immediate‑release tramadol history absent

    Claims for tramadol ER will require prior authorization if the patient's Independent Health prescription history does not document immediate‑release tramadol filled within the previous 90 days.

    Prior Authorization

    Trintellix: PA if no generic SSRI fill in prior 90 days

    Trintellix requires prior authorization if the pharmacy profile does not document a filled generic SSRI within the previous 90 days.

    Prior Authorization

    Febuxostat (Uloric): PA if no allopurinol fill in prior 90 days

    Febuxostat (Uloric) requires prior authorization when the pharmacy profile does not document an allopurinol fill within the previous 90 days.

    Prior Authorization

    Xphozah: PA if no concurrent phosphate binder use in prior 120 days

    A prescription for Xphozah (tenapanor) will require prior authorization if Independent Health prescription history does not document concurrent use of a phosphate binder within the previous 120 days; prescriber may request authorization via standard process when history is absent.

    Prior Authorization

    Sublingual zolpidem: PA if no generic zolpidem fill in prior 90 days

    Sublingual zolpidem requires prior authorization if the pharmacy profile does not document a generic zolpidem fill within the previous 90 days.

    Note

    Step therapy enforcement (ST designation and summary)

    Medications designated 'ST' on the formulary require trials of specified medications; this policy enforces step‑therapy behavior by using prior‑fill history as the prerequisite for online processing and routes claims to prior authorization when those prior‑fill criteria are not met.

    • 'ST' on formulary indicates step therapy requirement.
    • Absence of documented prior fills within the product‑specific lookback windows triggers PA.
    Step Therapy

    Prior‑fill history acts as step prerequisite

    The policy uses prior Independent Health prescription fills as step requirements: if the required prior fill is not present within the product's lookback window (90, 120, or 365 days as specified), the claim is routed to prior authorization.

    Step Therapy

    Opioid continuation: recent narcotic fill within 120 days required

    To avoid PA for high‑potency narcotics, the pharmacy profile must document a narcotic medication fill within the previous 120 days; absence of such documentation triggers prior authorization.

    Documentation Required

    Product‑specific prior‑fill/concurrent‑therapy requirements

    Each product in the list requires the pharmacy prescription history to document the specific prior fill or concurrent therapy and timeframe referenced in the policy (e.g., entacapone or levodopa‑carbidopa‑entacapone for Ongentys; oxcarbazepine within 90 days; immediate‑release tramadol within 90 days for tramadol ER).

    Billing Rule

    Tramadol ER: online processing allowed only with immediate‑release tramadol documented

    Online processing for tramadol ER is allowed only if Independent Health prescription history documents immediate‑release tramadol filled within the previous 90 days; otherwise a prior authorization is required.

    Billing Rule

    Trintellix: online processing requires prior generic SSRI fill

    For Trintellix, online processing is allowed only when the Independent Health prescription history documents a generic SSRI filled within the previous 90 days; otherwise prior authorization is required.

    Billing Rule

    Febuxostat (Uloric): online processing requires prior allopurinol fill

    For febuxostat (Uloric) 40 mg and 80 mg, online processing is allowed only if the prescription history documents an allopurinol fill within the previous 90 days; otherwise prior authorization is required.

    Billing Rule

    Xphozah: online processing requires documented phosphate binder use

    For Xphozah (tenapanor), online processing is allowed only if Independent Health prescription history documents concurrent phosphate binder use within the previous 120 days; otherwise prescriber must request authorization.

    Billing Rule

    Sublingual zolpidem: online processing requires prior generic zolpidem fill

    Sublingual zolpidem will process online only when Independent Health prescription history documents a generic zolpidem fill within the previous 90 days; absent that documentation, prior authorization is required.

    Documentation Required

    Document prior fills in Independent Health prescription history

    The pharmacy must document prior fills in the member's Independent Health prescription history to meet step therapy criteria; contact Member Services for questions about documentation or exceptions.

    • Document comparator drug name and fill date in Independent Health prescription history.
    • If history is incomplete, prescriber may submit PA via standard authorization process.
    Documentation Required

    Required pharmacy fill history for comparator medications

    Pharmacies must ensure the member's Independent Health prescription history documents the specified comparator medication(s) within the defined lookback windows (e.g., 90, 120, or 365 days) to allow online processing and avoid prior authorization.

    Documentation Required

    Narcotic fill documentation for high‑potency opioids (120‑day rule)

    For listed high‑potency narcotics, the pharmacy profile must document a prior narcotic fill within 120 days (per the policy's narcotic‑continuation requirement) to avoid prior authorization.

    Documentation Required

    Pharmacy history must list the exact comparator drug(s) and timeframe

    Pharmacy prescription history must document the specific drug(s) and timeframe referenced for each product (e.g., entacapone or levodopa‑carbidopa‑entacapone for Ongentys; oxcarbazepine within 90 days; atomoxetine for Qelbree) to permit online processing.

    Billing Rule

    Online processing requires documented recent fills in IH prescription history

    To process claims online, the Independent Health prescription history must show the recent fills within the product‑specific lookback windows (90 or 120 days as noted); otherwise the prescriber must request prior authorization through the standard process.

    Prior Authorization

    Aczone: PA if no generic dapsone 5% fill in prior 90 days

    For Aczone (dapsone 7.5% gel), prior authorization is required when the pharmacy profile does not document a generic 5% dapsone fill within the previous 90 days.

    Prior Authorization

    Bepotastine ophthalmic: PA if no Zaditor/Alaway OTC fill in prior 90 days

    For bepotastine ophthalmic solution, prior authorization is required when the pharmacy profile does not document a Zaditor or Alaway OTC fill within the previous 90 days.

    Prior Authorization

    GLP‑1 agents: PA if no type 2 diabetes diagnosis or prior oral antidiabetic (excl. metformin) within 130 days

    GLP‑1 antidiabetic agents require evidence of type 2 diabetes or a trial of any oral antidiabetic (excluding metformin) within the past 130 days; prior authorization is required if this is not documented in the pharmacy profile.

    Prior Authorization

    Antiemetics: PA if no ondansetron fill in prior 180 days

    Certain antiemetics require prior authorization when the pharmacy profile does not document a generic ondansetron fill within the previous 180 days.

    Prior Authorization

    Belsomra: PA if no generic zolpidem fill in prior 365 days

    Belsomra products require prior authorization if the pharmacy profile does not document a generic zolpidem fill within the previous 365 days.

    Prior Authorization

    Binosto: PA if no alendronate fill in prior 90 days

    Binosto requires prior authorization when the pharmacy profile does not document alendronate filled within the previous 90 days.

    Prior Authorization

    Bromfenac ophthalmic: PA if no generic bromfenac 0.09% fill in prior 90 days

    Bromfenac ophthalmic products require prior authorization if the pharmacy profile does not document generic bromfenac ophthalmic solution 0.09% once daily filled within the previous 90 days.

    Prior Authorization

    Entacapone/Ongentys: PA if no concurrent levodopa/carbidopa documented

    Entacapone/Ongentys require prior authorization when the pharmacy profile does not document concurrent use of a levodopa/carbidopa product.

    Prior Authorization

    NSAID comparator required for diclofenac potassium (migraine) packets

    Diclofenac potassium (migraine) packets require prior authorization if the pharmacy profile does not document a generic NSAID fill.

    Prior Authorization

    EUCRISA: prior topical therapy required (restated)

    This EUCRISA instruction restates that PA is required when tacrolimus, pimecrolimus, or a topical corticosteroid fill within the prior 365 days is not documented in the pharmacy profile.

    Denial Risk

    EUCRISA prior‑fill requirement (duplicate)

    This is a duplicate EUCRISA prior‑fill instruction: if tacrolimus, pimecrolimus, or a topical corticosteroid was not filled within the prior 365 days, prior authorization is required and the claim may be denied without it.

    Denial Risk

    90‑day prior‑fill enforcement summary

    Multiple products in the policy use 90‑day lookbacks; if the specified comparator fill is not documented within 90 days, prior authorization is required and the claim may be denied without it.

    Note

    High‑potency narcotics: 120‑day enforcement summary

    High‑potency narcotics are subject to a 120‑day prior‑fill enforcement rule: absence of documented narcotic fills within 120 days triggers prior authorization.

    Prior Authorization

    High‑potency opioid PA trigger (restated)

    Restatement: claims for the listed high‑potency opioids require documented narcotic medication filled within the previous 120 days; otherwise prior authorization is required.

    Prior Authorization

    Ongentys PA trigger (restated)

    Restatement: Ongentys requires documentation of entacapone or levodopa‑carbidopa‑entacapone use within 180 days; absence requires prior authorization.

    Prior Authorization

    Oxcarbazepine ER PA trigger (restated)

    Restatement: Oxcarbazepine ER requires a prior oxcarbazepine fill within 90 days to process online; otherwise prior authorization is required.

    Prior Authorization

    Qelbree PA trigger (restated)

    Restatement: Qelbree requires prior atomoxetine fill to avoid prior authorization.

    Prior Authorization

    Methylphenidate ER PA trigger (restated)

    Restatement: Quillichew/Quillivant XR requires a generic methylphenidate SR/ER fill within 90 days to process online; otherwise prior authorization is required.

    Prior Authorization

    Aliskiren PA trigger (restated)

    Restatement: Aliskiren requires prior ACE and ARB fills within 180 days to process online; otherwise prior authorization is required.

    Prior Authorization

    Sancuso PA trigger (restated)

    Restatement: Sancuso requires ondansetron fill within 180 days to process online; otherwise prior authorization is required.

    Prior Authorization

    Serevent Diskus PA trigger (restated)

    Restatement: Serevent Diskus requires documented concurrent inhaled corticosteroid or Spiriva use to process online; otherwise prior authorization is required.

    Prior Authorization

    Tazarotene PA trigger (restated)

    Restatement: Tazarotene topical requires tretinoin or adapalene fill within 90 days to process online; otherwise prior authorization is required.

    Prior Authorization

    Tramadol ER PA trigger (restated)

    Restatement: Tramadol ER requires an immediate‑release tramadol fill within 90 days to process online; otherwise prior authorization is required.

    Prior Authorization

    Tramadol ER prior authorization (duplicate)

    Duplicate: Tramadol ER prior authorization instruction (claims require PA if immediate‑release tramadol not documented in prior 90 days).

    Prior Authorization

    Trintellix PA trigger (restated)

    Restatement: Trintellix requires documentation of a generic SSRI filled within the previous 90 days to process online; otherwise prior authorization is required.

    Prior Authorization

    Febuxostat PA trigger (restated)

    Restatement: Febuxostat requires prior allopurinol fill within 90 days to process online; otherwise prior authorization is required.

    Prior Authorization

    Xphozah PA trigger (restated)

    Restatement: A prescription for Xphozah will require prior authorization if concurrent phosphate binder use within the previous 120 days is not documented in the prescription history.

    Prior Authorization

    Sublingual zolpidem PA trigger (restated)

    Restatement: Sublingual zolpidem requires a generic zolpidem fill within the previous 90 days for online processing; otherwise prior authorization is required.

    Policy Background

    Step therapy is a utilization management approach that requires trials of specified, typically lower‑cost or first‑line medications before coverage of alternatives. This policy operationalizes step therapy by using the member's Independent Health prescription history as the trigger: online claim processing is allowed when the pharmacy profile documents the required comparator fill or diagnosis within the stated lookback window (for example, 90 days for many agents, 120 days for listed high‑potency opioids, and 365 days for certain topical comparators). If the required prior fill or concurrent therapy is not documented in the pharmacy profile, the prescription is routed to prior authorization.

    Key Definitions

    inv-92: Step therapy (ST) definition — compact
    Step therapy (ST) — definitionA process requiring trial of specified medications prior to covering another medication for the same condition; ST‑designated drugs are marked 'ST' on the formulary.
    PurposeEnsures trials of typically lower‑cost or first‑line medications (often generics) before covering alternatives
    How identifiedMedications requiring step therapy are indicated with 'ST' in the formulary notes
    inv-93: high-potency narcotics — definition/key group note
    High‑potency narcotics — key group noteIncludes multiple high‑potency opioid ER formulations and fentanyl transdermal patches (e.g., fentanyl patches, hydrocodone ER ADF, hydromorphone ER, morphine ER, Nucynta ER, oxymorphone ER)
    Risk noteThese products pose serious risks if started in a narcotic‑naïve patient and therefore require documented narcotic fills within 120 days to process online
    Processing implicationIf pharmacy profile lacks narcotic fills in prior 120 days, prior authorization is required and prescription may be denied

    Initial Therapy Rules

    Initial therapy for GLP-1 antidiabetics

    GLP-1 agents require evidence of type 2 diabetes diagnosis or prior oral antidiabetic therapy (excluding metformin).

    GLP-1 prior requirement: Member has a documented diagnosis of type 2 diabetes OR has tried any oral antidiabetic medication excluding metformin within the past 130 days.130 days

    Initial therapy rules

    Initial dispensing rules based on prior therapy documentation in Independent Health prescription history.

    Tramadol ER initial: Requires prior documented fill of immediate-release tramadol within previous 90 days for online processing; prior authorization required otherwise.90 days
    Trintellix initial: Requires prior documented fill of a generic SSRI within previous 90 days for online processing; prior authorization required otherwise.90 days
    Febuxostat initial: Requires prior documented fill of allopurinol within previous 90 days for online processing; prior authorization required otherwise.90 days
    Xphozah initial: Requires documentation of concurrent phosphate binder use within previous 120 days for online processing; prescriber must request authorization if not documented.120 days
    Sublingual zolpidem initial: Requires prior documented fill of generic zolpidem within previous 90 days for online processing; prior authorization required otherwise.90 days

    Step Therapy Lookup Table

    RequirementLook-back windowIf not documented
    Document prior fills or diagnoses in the member's Independent Health prescription history for the specified comparator medication or condition
    90, 130, 180, or 365 days (varies by product)
    Claim routed to prior authorization; prior authorization required
    Drug / ComparatorRequired prior fill in pharmacy profileLook-back window
    Fetzima
    Venlafaxine extended‑release capsule fill documented in Independent Health pharmacy history
    90 days
    Glycopyrrolate products
    Generic glycopyrrolate tablet fill documented in pharmacy history
    90 days
    Gabapentin / Horizant
    Gabapentin fill documented in pharmacy history
    90 days
    Doxercalciferol / Rayaldee
    Calcitriol fill documented in pharmacy history
    90 days
    Hydrocortisone valerate ointment
    Triamcinolone fill documented in pharmacy history
    90 days
    Amphetamine–dextroamphetamine ER
    Amphetamine–dextroamphetamine ER fill documented in pharmacy history
    90 days
    Namzaric
    Donepezil or memantine fill documented in pharmacy history
    90 days
    RequirementLook-back windowIf not documented
    Pharmacy profile documents prior narcotic medication fills for the member (continuation/step requirement for listed high‑potency opioids)
    120 days
    Prior authorization required and claim may be denied without it
    ProductRequired documented therapyLook-back window / Action if absent
    Ongentys (opicapone)
    Concurrent use of entacapone or levodopa–carbidopa–entacapone documented in Independent Health pharmacy history
    180 days; prior authorization required if not documented
    ProductRequired documented therapyLook-back window / Action if absent
    Oxcarbazepine ER
    Oxcarbazepine fill documented in Independent Health pharmacy history
    90 days; prior authorization required if not documented
    ProductRequired documented therapyAction if absent
    Qelbree (viloxazine ER)
    Prior atomoxetine (Strattera) fill documented in Independent Health pharmacy history
    Prior authorization required if atomoxetine fill not documented
    ProductRequired documented therapyLook-back window / Action if absent
    Quillichew / Quillivant XR (methylphenidate ER formulations)
    Generic methylphenidate slow‑release or extended‑release product fill documented in pharmacy history
    90 days; prior authorization required if not documented
    ProductRequired documented therapyLook-back window / Action if absent
    Aliskiren fumarate
    Prior fills of an ACE inhibitor and an ARB documented in Independent Health pharmacy history
    180 days; prior authorization required if both are not documented
    ProductRequired documented therapyLook-back window / Action if absent
    Sancuso (ondansetron patch)
    Ondansetron fill documented in Independent Health pharmacy history
    180 days; prior authorization required if not documented
    ProductRequired documented therapyIf not documented
    Serevent Diskus (salmeterol)
    Concurrent use of an inhaled corticosteroid or Spiriva documented in pharmacy history
    Prior authorization required if concurrent therapy not documented
    ProductRequired documented therapyLook-back window / Action if absent
    Tazarotene topical (cream/gel)
    Tretinoin or adapalene fill documented in Independent Health pharmacy history
    90 days; prior authorization required if not documented
    ProductRequired documented therapyLook-back window / Action if absent
    Tramadol ER formulations
    Immediate‑release tramadol fill documented in Independent Health pharmacy history
    90 days; prior authorization required if not documented
    Consolidated requirementExamples (products)Look-back / Action if absent
    Online processing allowed only when the member's Independent Health prescription history documents the specific prior comparator therapy or concurrent medication listed for the product; otherwise prescriber must obtain prior authorization
    Examples: prior generic SSRI for Trintellix; allopurinol for febuxostat (Uloric); concurrent phosphate binder for Xphozah; generic zolpidem for sublingual zolpidem
    Generally 90 days (most comparators); 120 days for high‑potency opioids or tenapanor concurrent binder; 180 or 365 days for select products as specified — prior authorization required if not documented